Satellos Bioscience Inc. (TSX:MSCL)
Canada · Delayed Price · Currency is CAD | Market Cap | 278.72M +163.5% |
| Revenue (ttm) | n/a |
| Net Income | -49.15M |
| EPS | -2.83 |
| Shares Out | 20.83M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,883 |
| Open | 13.60 |
| Previous Close | 13.85 |
| Day's Range | 13.30 - 13.60 |
| 52-Week Range | 6.48 - 18.98 |
| Beta | 1.17 |
| Analysts | Strong Buy |
| Price Target | 17.67 (+32.06%) |
| Earnings Date | Aug 21, 2026 |
About Satellos Bioscience
Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research ... [Read more]
Analyst Summary
According to 3 analysts, the average rating for MSCL stock is "Strong Buy." The 12-month stock price target is $17.67, which is an increase of 32.06% from the latest price.
News
Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress
TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscl...
Satellos Bioscience Registration statement: Q2 2026
Satellos Bioscience filed a registration statement on August 13, 2026, providing details about a securities offering with the SEC.
Satellos Bioscience Registration statement: Q2 2026
Satellos Bioscience filed a registration statement on August 13, 2026, providing details about a securities offering with the SEC.
Satellos Bioscience Earnings release: Q2 2026
Satellos Bioscience released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Satellos files $300M mixed securities shelf
16:03 EDT Satellos (MSLE) files $300M mixed securities shelf
Satellos Bioscience Registration statement: Registration filing
Satellos Bioscience filed a registration statement on August 11, 2026, providing details about a securities offering with the SEC.
Satellos Bioscience DMD Drug Shows Early Promise in 6-Month Study Update
Satellos Bioscience NASDAQ: MSLE said interim six-month data from its ongoing TRAILHEAD study showed encouraging safety and efficacy signals for SAT-3247, its investigational therapy for Duchenne musc...
Satellos price target raised to $18 from $11 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Satellos (MSLE) to $18 from $11 and keeps a Buy rating on the shares after the company reported six-month interim data from…
Satellos Bioscience Inc TRAILHEAD Study Data Update Call Transcript
Satellos Bioscience Inc TRAILHEAD Study Data Update Call Transcript
Satellos Bioscience Transcript: Study update
Six-month interim data from the TRAILHEAD study in adults with DMD showed improvements in muscle fat fraction, upper limb effort, and quality of life, with a favorable safety profile and no serious adverse events. These results support further development and regulatory engagement for SAT-3247.
Satellos Bioscience Press release: Study update
Satellos Bioscience issued a press release on July 8, 2026, disclosing material business information to investors.
Satellos Bioscience Slides: Study update
Satellos Bioscience has posted slides in relation to its latest quarterly earnings report, which was published on July 8, 2026.
Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247
TORONTO, July 08, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat ...
Satellos Bioscience Slides: Corporate presentation
Satellos Bioscience has posted slides in relation to its latest quarterly earnings report, which was published on July 7, 2026.
Satellos' SAT-3247 Wins FDA Fast Track Status For Duchenne Muscular Dystrophy, Stock Up
(RTTNews) - Satellos Bioscience Inc. (MSLE), a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration has granted Fast Track Designation to SAT-3247 for the treatme...
Satellos Bioscience's Duchenne Drug SAT-3247 Wins FDA Fast Track Designation
(RTTNews) - Monday, Satellos Bioscience Inc. (MSLE) announced that the U.S. Food and Drug Administration has granted Fast Track designation to SAT-3247 for the treatment of Duchenne muscular dystrophy...
Satellos announces Fast Track designation for SAT-3247
Satellos (MSLE) announced that the FDA has granted Fast Track designation to SAT-3247 for the treatment of Duchenne. The company is currently advancing SAT-3247 through its ongoing Phase 2 BASECAMP…
Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy
TORONTO, June 29, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat ...
Top Biotech Gainers: TECH Bought Out, MSLE On Watch, KYMR Hits New High, What's The Buzz At SLS?
(RTTNews) - Today's top gainers in the biotech space include Bio-Techne, following acquisition news; Satellos Bioscience, gearing up to present new DMD data next month; and Kymera, which has revised i...
Satellos to Present Clinical Program Updates at ICNMD 2026
TORONTO, June 25, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat ...
Satellos Bioscience Announces Results of Annual Meeting of Shareholders
TORONTO, June 17, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines ...
Satellos Bioscience Transcript: Jefferies Global Healthcare Conference 2026
A novel small molecule therapy targeting muscle regeneration in DMD is advancing through two phase II trials, showing promising preclinical and clinical results, including sustained strength gains and a favorable safety profile. Full enrollment and top-line data are expected by year-end, with regulatory and financial milestones on track.
Satellos Bioscience Annual report
Satellos Bioscience has published an annual report on June 3, 2026.
Satellos to Participate in Upcoming Investor Conferences
TORONTO, May 27, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines t...
Satellos resumed with a Speculative Buy at Canaccord
Canaccord analyst Tania Armstrong-Whitworth resumed coverage of Satellos (MSLE) with a Speculative Buy rating and C$19 price target The company’s lead drug SAT-3247 is being developed for the treatmen...